Eurofins CDMO

Eurofins CDMO operates as a critical service provider within the biopharmaceutical ecosystem, offering comprehensive drug substance and drug product development and manufacturing for Biologics (mAbs, ADCs, cell & gene therapies) and Small Molecules. Its strategy is built on being an integrated, medium-sized CDMO within the vast Eurofins Scientific network, aiming to combine personalized client dedication with global scale, scientific rigor, and synergistic testing services. The company's mission is to compress drug development timelines and de-risk the path to market for its biopharma clients through its global facility footprint and end-to-end service offerings.

Integrated development and cGMP manufacturing platform for Small Molecules (API, solid-state, DP) and Biologics (mAbs, ADCs, cell & gene therapy starting materials, sterile fill/finish).

Competes against large full-service CDMOs (e.g., Lonza, Catalent), pure-play biologics specialists, and smaller niche players. Differentiates through its 'medium-sized' agility, integrated small molecule and biologics offerings, and the powerful backing of the Eurofins Scientific global testing network.